Dynamic computational modeling in the search for better breast cancer drug therapy

Pharmacogenomics

Volumn 8, Issue 12, 2007, Pages 1757-1761

  Faratian, Dana ^a   Moodie, Stuart L ^b   Harrison, David J ^a   Goryanin, Igor ^b  

^a Edinburgh Cancer Research Centre   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Breast cancer; Drug resistance; Gefinitib; Herceptin ; Pertuzumab; Systems biology; Tamoxifen

Indexed keywords

AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GEFITINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PROTEIN TYROSINE KINASE; TAMOXIFEN; TRASTUZUMAB;

APOPTOSIS; ARTICLE; BIOCHEMISTRY; BREAST CANCER; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RESEARCH; CELL FATE; CLINICAL TRIAL; COLON CANCER; DRUG DESIGN; DRUG RESEARCH; ENZYME INHIBITION; FINANCIAL MANAGEMENT; GENOMICS; HORMONAL THERAPY; HUMAN; INDIVIDUALIZATION; LUNG CANCER; MATHEMATICAL MODEL; MEDLINE; MORBIDITY; PATIENT SELECTION; PREDICTION; PROGNOSIS; PROTEIN PHOSPHORYLATION; PROTEOMICS; SENESCENCE; SYSTEMS BIOLOGY; TRANSCRIPTOMICS; TREATMENT OUTCOME; UNITED KINGDOM;

BREAST NEOPLASMS; FEMALE; HUMANS; MODELS, BIOLOGICAL; SYSTEMS BIOLOGY;

EID: 37649017916     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.12.1757     Document Type: Article

References (15)

1. Hatakeyama M, Kimura S, Naka T et al.: A computational model on the modulation of mitogen-activated protein kinase (MAPK) and Akt pathways in heregulin-induced Erb B signalling. Biochem. J. 373(Pt 2), 451-463 (2003).
2. Markevich NI, Hoek JB, Kholodenkc BN: Signaling switches and bistability arising from multisite phosphorylation in protein kinase cascades. J. Cell Biol. 164(3), 353-359 (2004).
3. FuB H, Dubitzky W, Downes CS, Kurth MJ: Mathematical models of cell cycle regulation. Brief Bioinform. 6(2), 163-177 (2005).
4. Kholodenko BN: Cell-signaling dynamics in time and space. Nat. Rev Mol. Cell Biol. 7(3), 165-176 (2006).
5. Dixon JM: The scientific value of preoperative studies and how they can be used. Breast Cancer Res. Treat. 87 (Suppi 1), S19-S26 (2004).
6. Arpino G, Gutierrez C, Weiss H et al.: Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J. Natl. Cancer Inst. 99(9). 694-705 (2007).
7. Blinov ML, Faeder JR, Goldstein B, Hlavacek WS: A network model of early events in epidermal growth factor receptor signaling that accounts for combinatorial complexity. Biosystem 83(2-3), 136-151 (2006).
8. Shankaran H, Wiley HS, Resat H: Modeling the effects of HER/ErbB1-3 coexpression on receptor dimerization and biological response. Biophys. J. 90(11), 3993-4009 (2006).
9. Carter TA, Wodicka LM, Shah NP et al.: Inhibition of drug-resistant mutants of ABL, KIT and EGF receptor kinases. Proc. Natl. Acad. Sci. USA 102(31), 11011-11016 (2005).
10. Noble D: Systems biology and the heart. Biosystems 83(2-3), 75-80 (2006).
11. Dowsett M, Smith IE, Ebbs SR et al.: Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J. Natl Cancer Inst. 99(2), 167-170 (2007).
12. Dowsett M, Smith IE, Ebbs SR et al.: Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clin. Cancer Res. 12(Suppl. 3 Pt 2), 1024S-1030S (2006).
13. Christopher R, Dhiman A, Fox J et al.: Data-driven computer simulation of human cancer cell. Ann. NY Acad. Sci. 1020, 132-153 (2004).
14. Janes KA, Albeck JG, Gaudet S, Sorger PK, Lauffenburger DA, Yaffe MB: A systems model of signaling identifies a molecular basis set for cytokine-induced apoptosis. Science 310(5754), 1646-1653 (2005).
15. Kunkel EJ, Plavec I, Nguyen D et al.: Rapid structure-activity and selectivity analysis of kinase inhibitors by BioMAP analysis in complex human primary cell-based models. Assay Drug Dev. Technol. 2(4), 431-441 (2004).